A solution of Hepatitis B surface antigen used to immunize against Hepatitis B
<0.001 EU per 1 μg of the peptide by the LAL method
Hepatitis B Vaccine (Recombinant)
Active immunization against hepatitis B virus infection. The vaccine will not protect against infection caused by hepatitis A and non-A non-B hepatitis viruses. As hepatitis D (caused by the delta agent) does not occur in the absence of hepatitis B infection or carrier state, it can be expected that hepatitis D will also be prevented by vaccination with hepatitis B virus vaccine. The vaccine can be administered at any age from birth onwards. It may be used to start a primary course of vaccination or as a booster dose. It may also be used to complete a primary course of vaccination started with plasma-derived or yeast-derived vaccines or as a booster dose in subjects who have previously received a primary course of vaccination with plasma-derived or yeast-derived vaccines. In areas of low prevalence of hepatitis B, vaccination is strongly recommended in subjects who are at increased risk of infection. These include the following groups: Health professionals: physicians and surgeons; oral surgeons and dentists; nurses, dental nurses, dental hygienists, podiatrists; IV teams and operating room personnel; paramedical personnel in close contact with patients; staff in hemodialysis, nephrology, hepatology, hematology and oncology units; laboratory personnel handling blood and other clinical specimens; blood bank and plasma fractionation workers; pathologists and morgue attendants; cleaning staff who handle waste in hospitals; emergency and first aid workers; ambulance staff; dental, medical and nursing students. Patients: patients receiving frequent blood transfusion or clotting factor concentrates, such as those in oncology units and those with thalassemia, sickle-cell anemia, cirrhosis, hemophilia, etc.; patients on hemodialysis; patients with type 2 diabetes. Personnel and residents of institutions: persons with frequent and/or close contacts with high-risk groups; prisoners and prison staff; residents and staff of institutions for the developmentally challenged (those who are in contact with aggressive biting residents being at highest risk). Persons at increased risk due to their sexual practices: males having sexual contact with other males; others with multiple sexual partners or with a recent history of sexually transmitted disease. Persons who use injectable drugs illicitly. Travellers to areas of high endemicity and their close contacts. Household contacts of any of the above groups and of patients with acute or chronic hepatitis B infection. Infants born of HBsAg-positive mothers. Chronic Liver Disease (CLD): subjects with chronic liver disease; subjects at risk of developing CLD (e.g. Hepatitis C virus carriers, persons who abuse alcohol). Others: police; fire fighters; armed forces personnel; morticians and embalmers; those who through their work or personal lifestyle may be exposed to the hepatitis B virus. In areas of both low and high prevalence, vaccination should be offered to all young children and neonates at risk, as well as to adult high risk groups.
Examples of Clinical Use:
Hepatitis B virus infection
It induces specific humoral antibodies against the surface antigen of hepatitis B virus (anti-HBs antibodies). An anti-HBs antibody titre above 10 IU/l correlates with protection to HBV infection.
Mechanism of action:
It induces specific humoral antibodies against HBsAg (anti-HBs antibodies). It is generally accepted that an anti-HBs titre greater than 10 IU/L correlates with protection against hepatitis B virus infection. More than 90% of healthy adults, children and neonates developed protective anti-HBs titres one month after completing a primary vaccination schedule of ENGERIX®-B (hepatitis B vaccine (recombinant)).
Hepatitis B virus (HBV) is a pathogen that causes hepatitis B (hepatitis B for short) and belongs to the family Hepadnaviridae and the genus Orthohepadnavirus. HBV is transmitted through the blood or other body fluids of infected persons (daily work or life without blood exposure contact, generally will not infect HBV), causing liver cell inflammation, necrosis, and fibrosis. Hepatitis B is divided into acute and chronic 2 kinds. Acute hepatitis B can heal itself in 90% of adults, and chronic hepatitis B can develop into cirrhosis and even liver cancer.
After HBV invades the human body, it binds to the receptors on the liver cell membrane, removes the envelope, penetrates the liver cytoplasm, and then removes the capsid. Part of double-linked looped HBV DNA enters the liver nucleus. Under the action of host enzymes, the negative strand DNA is used as a template to extend the positive strand, repair the fenced region in the positive strand, and form covalently closed circular DNA (cccDNA). Then, using cccDNA as a template, several mRNA with different lengths were transcribed under the action of host RNA polymerase II. The progeny in the cytoplasm can also enter the liver nucleus to form cccDNA and continue to replicate. cccDNA has a long half-life (decay) period and is difficult to eliminate from the body.
As there is no effective cure for hepatitis B, once infected with hepatitis B virus and develop into chronic hepatitis, it is difficult to completely cure, therefore, the prevention of HBV infection is particularly important. Vaccination with hepatitis B vaccine (HepB) is the most effective way to prevent HBV infection.
2. Clinical application
Hepatitis B vaccine antigen (recombinant) is a vaccine used to prevent hepatitis B. The vaccine is administered with hepatitis B virus surface antigen (HBsAg) to stimulate an immune response in the body, thereby preventing the infection and development of hepatitis B. Hepatitis B vaccine antigen (recombinant) is widely used in the following areas:
Prevention of hepatitis B: The vaccine is one of the most effective means of preventing hepatitis B, and hepatitis B infection can be prevented by injection.
Treatment of hepatitis B: Hepatitis B vaccine antigen (recombinant) can be used to treat patients with hepatitis B, and more research needs to be done in terms of treatment.
For medical research: Hepatitis B vaccine antigen (recombinant) can also be used as a tool in the field of medical research to further explore the pathology and treatment of hepatitis B.
In conclusion, the hepatitis B vaccine antigen (recombinant) has a wide range of application prospects in the prevention and treatment of hepatitis B.
3. Action mechanism
The mechanism of action of the hepatitis B vaccine antigen (recombinant) is to prevent infection by the hepatitis B virus by activating the immune system. The vaccine contains recombinant proteins that are similar to the surface of the hepatitis B virus, and when inoculated, the body produces antibodies against these proteins. If the vaccinated person comes into contact with the hepatitis B virus, the body's antibodies will recognize and destroy the virus, thereby preventing infection.
In addition, the recombinant protein of hepatitis B vaccine antigen is safer and more efficient than traditional vaccine antigen production methods, and can simultaneously prevent infection of multiple subtypes of hepatitis B virus.
4. Merits and demerits
Prevent hepatitis B. Hepatitis B is a serious infectious disease, but vaccination against hepatitis B can protect a person from infection.
High security. Vaccines made using recombinant vaccine technology are relatively safe because they cannot be replicated or passed on as infectious diseases.
Long-lasting immune effect. Studies have shown that the immune effect of the hepatitis B vaccine lasts for many years after vaccination and has a long-term protective effect.
Possible side effects after vaccination. Although rare, it is possible to experience discomfort after vaccination, such as fever, headache, muscle pain, etc.
If not vaccinated at the right time, it may affect the immune effect. The hepatitis B vaccine needs to be administered according to a certain schedule, and if the time is missed, the immune effect will be affected.
Vaccine costs are high. The hepatitis B vaccine is more expensive than other vaccines and may be less friendly to certain populations.
In general, Hepatitis B Vaccine Antigen (Recombinant) has a reliable preventive effect as a vaccine against hepatitis B, but it is necessary to pay attention to its possible side effects and the correct time of vaccination.
5. Research progress
Vaccines are a very effective tool for preventing disease, which can help people build immunity and prevent the spread of disease. Hepatitis B vaccine antigen has been approved by the FDA to prevent the development of liver-related diseases such as cirrhosis and liver cancer.
For research use only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products
without prior written approval from Creative BioMart.
For more information on how our products could help advance your project, please contact us.